Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln

Cumberland Pharmaceuticals

05/05/2026 23:26

Overview

US specialty pharma firm's Q1 revenue rose 5% yr/yr, excluding prior-year milestone payment

Adjusted loss per share for Q1 was $0.13

Company to sell FDA-approved brands to Apotex for $100 mln, pending shareholder approval

Outlook

Company expects to focus on advancing pipeline after divesting FDA-approved brands to Apotex

Cumberland to retain development programs and majority ownership in Cumberland Emerging Technologies post-transaction

Company highlights ongoing clinical trials for ifetroban in DMD, SSc, and IPF with regulatory milestones pending

Result Drivers

PRODUCT PORTFOLIO - Q1 revenue growth was driven by sales from FDA-approved brands including Sancuso, Vibativ, Talicia, Kristalose and Caldolor

STRATEGIC TRANSACTION - Co announced agreement to sell its FDA-approved brands to Apotex for $100 mln, aiming to focus on pipeline development

PIPELINE FOCUS - Co highlighted progress in clinical programs for ifetroban, including Fast Track Designation from the FDA.

Company press release: ID:nPn2F6vNra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$9.10 mln
Q1 Adjusted EPS
-$0.13


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)